SG11201908788YA - Combinations of chk1- and wee1 - inhibitors - Google Patents

Combinations of chk1- and wee1 - inhibitors

Info

Publication number
SG11201908788YA
SG11201908788YA SG11201908788YA SG11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA SG 11201908788Y A SG11201908788Y A SG 11201908788YA
Authority
SG
Singapore
Prior art keywords
international
suite
cascadian
seattle
ave
Prior art date
Application number
Other languages
English (en)
Inventor
Alex Vo
Kevin Klucher
Scott Peterson
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201908788YA publication Critical patent/SG11201908788YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201908788Y 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors SG11201908788YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762480101P 2017-03-31 2017-03-31
PCT/US2018/025464 WO2018183891A1 (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Publications (1)

Publication Number Publication Date
SG11201908788YA true SG11201908788YA (en) 2019-10-30

Family

ID=62002508

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908788Y SG11201908788YA (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Country Status (11)

Country Link
US (1) US20200108074A1 (he)
EP (1) EP3600247A1 (he)
JP (1) JP2020512977A (he)
KR (1) KR20190130621A (he)
CN (1) CN110678169A (he)
AU (1) AU2018243667A1 (he)
CA (1) CA3058457A1 (he)
IL (1) IL269409A (he)
MX (1) MX2019011506A (he)
SG (1) SG11201908788YA (he)
WO (1) WO2018183891A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
EP3952877A4 (en) 2019-04-09 2022-12-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
JP2022554157A (ja) * 2019-10-25 2022-12-28 アストラゼネカ・アクチエボラーグ がんを処置する方法
JPWO2021172582A1 (he) * 2020-02-27 2021-09-02
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
CN115778962A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 治疗男性食管癌患者的药物及其相关应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
JPH07507768A (ja) 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003010444A1 (en) 2001-07-23 2003-02-06 Shock-Proof Solutions Pty Ltd Mechanical shock absorbing apparatus
BRPI0412820A (pt) 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050176733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2006014359A2 (en) 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting chk1
AU2005272586A1 (en) 2004-08-19 2006-02-23 Icos Corporation Compounds useful for inhibiting CHK1
NZ561458A (en) * 2005-03-29 2011-03-31 Icos Corp Heteroaryl urea derivatives useful for inhibiting CHK1
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CN101686675A (zh) 2007-03-20 2010-03-31 史密丝克莱恩比彻姆公司 化合物
HUE032403T2 (en) 2007-06-15 2017-09-28 Msd Kk Bicycloaniline derivative
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
WO2010098367A1 (en) 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
RU2017127088A (ru) * 2010-11-16 2019-02-04 Эррэй Биофарма Инк. Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
JP2015511245A (ja) 2012-02-23 2015-04-16 アッヴィ・インコーポレイテッド ピリドピリミジノン系キナーゼ阻害薬
EP3210980B1 (en) * 2012-05-15 2024-04-03 Cancer Research Technology Ltd Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017216559A1 (en) 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2020512977A (ja) 2020-04-30
AU2018243667A1 (en) 2019-10-17
CN110678169A (zh) 2020-01-10
MX2019011506A (es) 2019-11-01
IL269409A (he) 2019-11-28
US20200108074A1 (en) 2020-04-09
CA3058457A1 (en) 2018-10-04
KR20190130621A (ko) 2019-11-22
EP3600247A1 (en) 2020-02-05
WO2018183891A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
SG11201908788YA (en) Combinations of chk1- and wee1 - inhibitors
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201907034PA (en) Methods of treating influenza
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201903155XA (en) Pharmaceutical compounds
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201805645QA (en) Lsd1 inhibitors
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201909676WA (en) Treatment of her2 positive cancers
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders